{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:32:58Z","timestamp":1794551578932,"version":"4.9.1"},"reference-count":75,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"DOI":"10.13039\/501100002850","name":"National Fund for Science and Technological Development","doi-asserted-by":"publisher","award":["1200944"],"award-info":[{"award-number":["1200944"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013928","name":"Millennium Science Initiative Program, Millennium Institute on Immunology and Immunotherapy","doi-asserted-by":"publisher","award":["ICN09_016 \/ ICN 2021_045"],"award-info":[{"award-number":["ICN09_016 \/ ICN 2021_045"]}],"id":[{"id":"10.13039\/501100013928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013928","name":"Millennium Science Initiative Program, Millennium Institute on Immunology and Immunotherapy","doi-asserted-by":"publisher","award":["P09\/016-F"],"award-info":[{"award-number":["P09\/016-F"]}],"id":[{"id":"10.13039\/501100013928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013908","name":"Proyecto N\u00facleo UNAB","doi-asserted-by":"publisher","award":["DI-03-23\/NUC"],"award-info":[{"award-number":["DI-03-23\/NUC"]}],"id":[{"id":"10.13039\/501100013908","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPPS"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Ursodeoxycholic acid (UDCA) is a natural substance physiologically produced in the liver.\nInitially used to dissolve gallstones, it is now successfully used in treating primary biliary cirrhosis\nand as adjuvant therapy for various hepatobiliary cholestatic diseases. However, the mechanisms\nunderlying its beneficial effects still need to be clarified. Evidence suggests three mechanisms\nof action for UDCA that could benefit humans with cholestatic liver disease (CLD): protection\nof cholangiocytes against hydrophobic bile acid (BA) cytotoxicity, stimulation of hepatobiliary\nexcretion, and protection of hepatocytes against BA-induced apoptosis. These mechanisms\nmay act individually or together to potentiate them. At the molecular level, it has been observed\nthat UDCA can generate modifications in the transcription and translation of proteins essential in\nthe transport of BA, correcting the deficit in BA secretion in CLD, in addition to activating signaling\npathways to translocate these transporters to the sites where they should fulfill their function. Inhibition\nof BA-induced hepatocyte apoptosis may play a role in CLD, characterized by BA retention\nin the hepatocyte. Thus, different mechanisms of action contribute to the improvement after\nUDCA administration in CLD. On the other hand, the effects of UDCA on tissues that possess receptors\nthat may interact with BAs in pathological contexts, such as skeletal muscle, are still unclear.\nThis work aims to describe the main molecular mechanisms by which UDCA acts in the human\nbody, emphasizing the interaction in tissues other than the liver.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1389203724666230818092800","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T07:06:36Z","timestamp":1692342396000},"page":"206-214","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Bile Acids as Signaling Molecules: Role of Ursodeoxycholic Acid in\nCholestatic Liver Disease"],"prefix":"10.2174","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-6456","authenticated-orcid":true,"given":"Eduardo","family":"Cifuentes-Silva","sequence":"first","affiliation":[{"name":"Laboratory of Muscle Pathology, Fragility, and Aging, Faculty of Life Sciences, Universidad Andres Bello, Santiago,\nChile"},{"name":"Millennium Institute on Immunology and Immunotherapy, Faculty of Life Sciences, Universidad Andres Bello,\nSantiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Cabello-Verrugio","sequence":"additional","affiliation":[{"name":"Laboratory of Muscle Pathology, Fragility, and Aging, Faculty of Life Sciences, Universidad Andres Bello, Santiago,\nChile"},{"name":"Millennium Institute on Immunology and Immunotherapy, Faculty of Life Sciences, Universidad Andres Bello,\nSantiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3748\/wjg.15.804","volume":"15","author":"Monte M.J.","year":"2009","unstructured":"Monte M.J.; Marin J.J.G.; Antelo A.; Vazquez-Tato J.; Bile acids: Chemistry, physiology, and pathophysiology. World J Gastroenterol  2009,15(7),804-816","journal-title":"World J Gastroenterol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1194\/jlr.R900010-JLR200","volume":"50","author":"Chiang J.Y.L.","year":"2009","unstructured":"Chiang J.Y.L.; Bile acids: Regulation of synthesis. J Lipid Res  2009,50(10),1955-1966","journal-title":"J Lipid Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0300-9084(93)90073-2","volume":"75","author":"Pedersen J.I.","year":"1993","unstructured":"Pedersen J.I.; Peroxisomal oxidation of the steroid side chain in bile acid formation. Biochimie  1993,75(3-4),159-165","journal-title":"Biochimie"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/4847941","volume":"2021","author":"Orozco-Aguilar J.","year":"2021","unstructured":"Orozco-Aguilar J.; Simon F.; Cabello-Verrugio C.; Redoxdependent effects in the physiopathological role of bile acids. Oxid Med Cell Longev  2021,2021,1-15","journal-title":"Oxid Med Cell Longev"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"119252","DOI":"10.1016\/j.lfs.2021.119252","volume":"272","author":"Zangerolamo L.","year":"2021","unstructured":"Zangerolamo L.; Vettorazzi J.F.; Rosa L.R.O.; Carneiro E.M.; Barbosa H.C.L.; The bile acid TUDCA and neurodegenerative disorders: An overview. Life Sci  2021,272,119252","journal-title":"Life Sci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.colsurfa.2006.02.009","volume":"280","author":"Warren D.B.","year":"2006","unstructured":"Warren D.B.; Chalmers D.K.; Hutchison K.; Dang W.; Pouton C.W.; Molecular dynamics simulations of spontaneous bile salt aggregation. Colloids Surf A Physicochem Eng Asp  2006,280(1-3),182-193","journal-title":"Colloids Surf A Physicochem Eng Asp"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/00365529409103618","volume":"29","author":"Hofmann A.F.","year":"1994","unstructured":"Hofmann A.F.; Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol  1994,29,1-15","journal-title":"Scand J Gastroenterol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cphy.c120023","volume":"3","author":"Chiang J.Y.","year":"2013","unstructured":"Chiang J.Y.; Bile acid metabolism and signaling. Compr Physiol  2013,3(3),1191-1212","journal-title":"Compr Physiol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"G494","DOI":"10.1152\/ajpgi.00156.2003","volume":"285","author":"Wang D.Q.H.","year":"2003","unstructured":"Wang D.Q.H.; Tazuma S.; Cohen D.E.; Carey M.C.; Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption : Studies in the gallstonesusceptible mouse. Am J Physiol Gastrointest Liver Physiol  2003,285(3),G494-G502","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.apsb.2015.01.004","volume":"5","author":"Ding L.","year":"2015","unstructured":"Ding L.; Yang L.; Wang Z.; Huang W.; Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm Sin B  2015,5(2),135-144","journal-title":"Acta Pharm Sin B"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.dld.2013.10.021","volume":"46","author":"Duboc H.","year":"2014","unstructured":"Duboc H.; Tach\u00e9 Y.; Hofmann A. F.; The bile acid TGR5 membrane receptor: From basic research to clinical application Digestive and Liver Dis  2014,46(4),302-312","journal-title":"Digestive and Liver Dis"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"G175","DOI":"10.1152\/ajpgi.00409.2002","volume":"284","author":"Wolkoff A.W.","year":"2003","unstructured":"Wolkoff A.W.; Cohen D.E.; I. Hepatocyte transport of bile acids. Am J Physiol Gastrointest Liver Physiol  2003,284(2),G175-G179","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.apsb.2015.01.006","volume":"5","author":"Ridlon J.M.","year":"2015","unstructured":"Ridlon J.M.; Bajaj J.S.; The human gut sterolbiome : Bile acid-microbiome endocrine aspects and therapeutics. Acta Pharm Sin B  2015,5(2),99-105","journal-title":"Acta Pharm Sin B"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3109\/03602532.2012.740048","volume":"45","author":"Li T.","year":"2013","unstructured":"Li T.; Chiang J.Y.L.; Nuclear receptors in bile acid metabolism. Drug Metab Rev  2013,45(1),145-155","journal-title":"Drug Metab Rev"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","volume":"72","author":"Russell D.W.","year":"2003","unstructured":"Russell D.W.; The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem  2003,72(1),137-174","journal-title":"Annu Rev Biochem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"41690","DOI":"10.1074\/jbc.M105117200","volume":"276","author":"Zhang M.","year":"2001","unstructured":"Zhang M.; Chiang J.Y.L.; Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (CYP8B1): roles of heaptocyte nuclear factor 4alpha in mediating bile acid repression. J Biol Chem  2001,276(45),41690-41699","journal-title":"J Biol Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/0004563218817798","volume":"56","author":"McGlone E.R.","year":"2019","unstructured":"McGlone E.R.; Bloom S.R.; Bile acids and the metabolic syndrome. Ann Clin Biochem  2019,56(3),326-337","journal-title":"Ann Clin Biochem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2132903","DOI":"10.1080\/19490976.2022.2132903","volume":"14","author":"Lee J.W.","year":"2022","unstructured":"Lee J.W.; Cowley E.S.; Wolf P.G.; Doden H.L.; Murai T.; Caicedo K.Y.O.; Ly L.K.; Sun F.; Takei H.; Nittono H.; Daniel S.L.; Cann I.; Gaskins H.R.; Anantharaman K.; Alves J.M.P.; Ridlon J.M.; Formation of secondary allobile acids by novel enzymes from gut firmicutes. Gut Microb  2022,14(1),2132903","journal-title":"Gut Microb"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1574-6968.2004.tb09568.x","volume":"235","author":"Lepercq P.","year":"2004","unstructured":"Lepercq P.; G\u00e9rard P.; B\u00e9guet F.; Raibaud P.; Grill J.P.; Relano P.; Cayuela C.; Juste C.; Epimerization of chenodeoxycholic acid to ursodeoxycholic acid by clostridium baratii isolated from human feces. FEMS Microbiol Lett  2004,235(1),65-72","journal-title":"FEMS Microbiol Lett"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1631\/jzus.B1900073","volume":"20","author":"Jia E.","year":"2019","unstructured":"Jia E.; Liu Z.; Pan M.; Lu J.; Ge Q.; Regulation of bile acid metabolismrelated signaling pathways by gut microbiota in diseases. J Zhejiang Univ Sci B  2019,20(10),781-792","journal-title":"J Zhejiang Univ Sci B"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.bbadis.2017.09.019","volume":"1864","author":"Cariello M.","year":"2018","unstructured":"Cariello M.; Piccinin E.; Garcia-Irigoyen O.; Sabb\u00e0 C.; Moschetta A.; Nuclear receptor FXR, bile acids and liver damage : Introducing the progressive familial intrahepatic cholestasis with FXR mutations. Biochim Biophys Acta Mol Basis Dis  2018,1864(4)(4 Pt B),1308-1318","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1073\/pnas.0400046101","volume":"101","author":"Bishop-Bailey D.","year":"2004","unstructured":"Bishop-Bailey D.; Walsh D.T.; Warner T.D.; Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci USA  2004,101(10),3668-3673","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.gdata.2015.07.026","volume":"6","author":"Gui T.","year":"2015","unstructured":"Gui T.; Gai Z.; Genome-wide profiling to analyze the effects of FXR activation on mouse renal proximal tubular cells. Genom Data  2015,6,31-32","journal-title":"Genom Data"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/164_2019_236","volume":"256","author":"Shin D.J.","year":"2019","unstructured":"Shin D.J.; Wang L.; Bile acid-activated receptors: A review on FXR and other nuclear receptors. Handb Exp Pharmacol  2019,256,51-72","journal-title":"Handb Exp Pharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1194\/jlr.M700330-JLR200","volume":"48","author":"Kim I.","year":"2007","unstructured":"Kim I.; Ahn S.H.; Inagaki T.; Choi M.; Ito S.; Guo G.L.; Kliewer S.A.; Gonzalez F.J.; Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res  2007,48(12),2664-2672","journal-title":"J Lipid Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","volume":"2","author":"Inagaki T.","year":"2005","unstructured":"Inagaki T.; Choi M.; Moschetta A.; Peng L.; Cummins C.L.; McDonald J.G.; Luo G.; Jones S.A.; Goodwin B.; Richardson J.A.; Gerard R.D.; Repa J.J.; Mangelsdorf D.J.; Kliewer S.A.; Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab  2005,2(4),217-225","journal-title":"Cell Metab"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/sj.bjp.0707235","volume":"151","author":"Teng S.","year":"2007","unstructured":"Teng S.; Piquette-Miller M.; Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis. Br J Pharmacol  2007,151(3),367-376","journal-title":"Br J Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1210\/me.2009-0482","volume":"24","author":"Han S.","year":"2010","unstructured":"Han S.; Li T.; Ellis E.; Strom S.; Chiang J.Y.L.; A novel bile acidactivated vitamin D receptor signaling in human hepatocytes. Mol Endocrinol  2010,24(6),1151-1164","journal-title":"Mol Endocrinol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0378-1119(00)00518-7","volume":"262","author":"Chiang J.Y.L.","year":"2001","unstructured":"Chiang J.Y.L.; Kimmel R.; Stroup D.; Regulation of cholesterol 7\u03b1-hydroxylase gene ( CYP7A1 ) transcription by the liver orphan receptor (LXR\u03b1). Gene  2001,262(1-2),257-265","journal-title":"Gene"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"9435","DOI":"10.1074\/jbc.M209706200","volume":"278","author":"Kawamata Y.","year":"2003","unstructured":"Kawamata Y.; Fujii R.; Hosoya M.; Harada M.; Yoshida H.; Miwa M.; Fukusumi S.; Habata Y.; Itoh T.; Shintani Y.; Hinuma S.; Fujisawa Y.; Fujino M.; A G protein-coupled receptor responsive to bile acids. J Biol Chem  2003,278(11),9435-9440","journal-title":"J Biol Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.drudis.2009.02.005","volume":"14","author":"Tiwari A.","year":"2009","unstructured":"Tiwari A.; Maiti P.; TGR5: An emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders. Drug Discov Today  2009,14(9-10),523-530","journal-title":"Drug Discov Today"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1124\/pr.113.008201","volume":"66","author":"Li T.","year":"2014","unstructured":"Li T.; Chiang J.Y.L.; Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev  2014,66(4),948-983","journal-title":"Pharmacol Rev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1172\/JCI76289","volume":"124","author":"Perino A.","year":"2014","unstructured":"Perino A.; Pols T.W.H.; Nomura M.; Stein S.; Pellicciari R.; Schoonjans K.; TGR5 reduces macrophage migration through mTOR-induced C\/EBP\u03b2 differential translation. J Clin Invest  2014,124(12),5424-5436","journal-title":"J Clin Invest"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3389\/fphys.2016.00646","volume":"7","author":"Guo C.","year":"2016","unstructured":"Guo C.; Chen W.D.; Wang Y.D.; TGR5, Not only a metabolic regulator. Front Physiol  2016,7,646","journal-title":"Front Physiol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/hep.24525","volume":"54","author":"Wang Y.D.","year":"2011","unstructured":"Wang Y.D.; Chen W.D.; Yu D.; Forman B.M.; Huang W.; The G-Protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-\u03baB) in mice. Hepatology  2011,54(4),1421-1432","journal-title":"Hepatology"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3389\/fphar.2015.00287","volume":"6","author":"Guo C.","year":"2015","unstructured":"Guo C.; Qi H.; Yu Y.; Zhang Q.; Su J.; Yu D.; Huang W.; Chen W.D.; Wang Y.D.; The G-protein-coupled bile acid receptor Gpbar1 (TGR5) inhibits gastric inflammation through antagonizing NF-\u03baB signaling pathway. Front Pharmacol  2015,6,287","journal-title":"Front Pharmacol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1161\/ATVBAHA.113.301565","volume":"33","author":"Kida T.","year":"2013","unstructured":"Kida T.; Tsubosaka Y.; Hori M.; Ozaki H.; Murata T.; Bile acid receptor TGR5 agonism induces no production and reduces monocyte adhesion in vascular endothelial cells. Arterioscler Thromb Vasc Biol  2013,33(7),1663-1669","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"7922","DOI":"10.3390\/ijms21217922","volume":"21","author":"Abrigo J.","year":"2020","unstructured":"Abrigo J.; Campos F.; Gonzalez F.; Aguirre F.; Gonzalez A.; Huerta-Salgado C.; Conejeros S.; Simon F.; Arrese M.; Cabrera D.; Elorza A.A.; Cabello-Verrugio C.; Sarcopenia induced by chronic liver disease in mice requires the expression of the bile acids membrane receptor TGR5. Int J Mol Sci  2020,21(21),7922","journal-title":"Int J Mol Sci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/jcp.29839","volume":"236","author":"Abrigo J.","year":"2021","unstructured":"Abrigo J.; Gonzalez F.; Aguirre F.; Tacchi F.; Gonzalez A.; Meza M.P.; Simon F.; Cabrera D.; Arrese M.; Karpen S.; Cabello-Verrugio C.; Cholic acid and deoxycholic acid induce skeletal muscle atrophy through a mechanism dependent on TGR5 receptor. J Cell Physiol  2021,236(1),260-272","journal-title":"J Cell Physiol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3390\/life11040349","volume":"11","author":"Son S.W.","year":"2021","unstructured":"Son S.W.; Song D.S.; Chang U.I.; Yang J.M.; Definition of sarcopenia in chronic liver disease. Life  2021,11(4),349","journal-title":"Life"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2353\/ajpath.2007.061133","volume":"171","author":"Fickert P.","year":"2007","unstructured":"Fickert P.; St\u00f6ger U.; Fuchsbichler A.; Moustafa T.; Marschall H.U.; Weiglein A.H.; Tsybrovskyy O.; Jaeschke H.; Zatloukal K.; Denk H.; Trauner M.; A new xenobioticinduced mouse model of sclerosing cholangitis and biliary fibrosis. Am J Pathol  2007,171(2),525-536","journal-title":"Am J Pathol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2174\/1566524019666190917124636","volume":"20","author":"Abrigo J.","year":"2019","unstructured":"Abrigo J.; Mar\u00edn T.; Aguirre F.; Tacchi F.; Vilos C.; Simon F.; Arrese M.; Cabrera D.; Cabello-Verrugio C.; N-acetyl cysteine attenuates the sarcopenia and muscle apoptosis induced by chronic liver disease. Curr Mol Med  2019,20(1),60-71","journal-title":"Curr Mol Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00424-018-2167-3","volume":"470","author":"Campos F.","year":"2018","unstructured":"Campos F.; Abrigo J.; Aguirre F.; Garc\u00e9s B.; Arrese M.; Karpen S.; Cabrera D.; And\u00eda M.E.; Simon F.; Cabello-Verrugio C.; Sarcopenia in a mice model of chronic liver disease : Role of the ubiquitin\u2013proteasome system and oxidative stress. Pflugers Arch  2018,470(10),1503-1519","journal-title":"Pflugers Arch"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"e80638","DOI":"10.7554\/eLife.80638","volume":"11","author":"Tamai Y.","year":"2022","unstructured":"Tamai Y.; Eguchi A.; Shigefuku R.; Kitamura H.; Tempaku M.; Sugimoto R.; Kobayashi Y.; Iwasa M.; Takei Y.; Nakagawa H.; Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in cultured mouse myotubes, chronic liver disease rats and humans. eLife  2022,11,e80638","journal-title":"eLife"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00018-008-7568-6","volume":"65","author":"Hofmann A.F.","year":"2008","unstructured":"Hofmann A.F.; Hagey L.R.; Bile acids : Chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci  2008,65(16),2461-2483","journal-title":"Cell Mol Life Sci"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/B978-1-4377-3796-7.00053-7","author":"Hope A.A.","year":"2013","unstructured":"Hope A.A.; Morrison R.S.;  Evidence-Based Practice in Palliative Medicine  2013,300-307","journal-title":"Evidence-Based Practice in Palliative Medicine"},{"key":"ref=47","first-page":"2650","volume":"18","author":"Moon A. M.","year":"2020","unstructured":"Moon A. M.; Singal A. G.; Tapper E. B.; Contemporary epidemiology of chronic liver disease and cirrhosis. Clingastroenterol hepatol  2020,18(12),2650-2666","journal-title":"Clingastroenterol hepatol"},{"key":"ref=48","doi-asserted-by":"publisher","DOI":"10.1177\/1756284818787400","volume":"11","author":"Santiago P.","year":"2018","unstructured":"Santiago P.; Scheinberg A.R.; Levy C.; Cholestatic liver diseases: New targets, new therapies. Ther Adv Gastroenterol  2018,11","journal-title":"Ther Adv Gastroenterol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","volume":"386","author":"Carey E.J.","year":"2015","unstructured":"Carey E.J.; Ali A.H.; Lindor K.D.; Primary biliary cirrhosis. Lancet  2015,386(10003),1565-1575","journal-title":"Lancet"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","volume":"67","author":"Karlsen T.H.","year":"2017","unstructured":"Karlsen T.H.; Folseraas T.; Thorburn D.; Vesterhus M.; Primary sclerosing cholangitis : A comprehensive review. J Hepatol  2017,67(6),1298-1323","journal-title":"J Hepatol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1089-3261(03)00135-1","volume":"8","author":"Paumgartner G.","year":"2004","unstructured":"Paumgartner G.; Beuers U.; Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis  2004,8(1),67-81, vi","journal-title":"Clin Liver Dis"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"107396","DOI":"10.1016\/j.pharmthera.2019.107396","volume":"203","author":"Goossens J.F.","year":"2019","unstructured":"Goossens J.F.; Bailly C.; Ursodeoxycholic acid and cancer : From chemoprevention to chemotherapy. Pharmacol Ther  2019,203,107396","journal-title":"Pharmacol Ther"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0168-8278(01)00092-7","volume":"35","author":"Lazaridis K.N.","year":"2001","unstructured":"Lazaridis K.N.; Gores G.J.; Lindor K.D.; Ursodeoxycholic acid \u2018mechanisms of action and clinical use in hepatobiliary disorders\u2019. J Hepatol  2001,35(1),134-146","journal-title":"J Hepatol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/ncpgasthep0521","volume":"3","author":"Beuers U.","year":"2006","unstructured":"Beuers U.; Drug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol  2006,3(6),318-328","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/clpt.2012.79","volume":"92","author":"K\u00f6ck K.","year":"2012","unstructured":"K\u00f6ck K.; Brouwer K.L.R.; A perspective on efflux transport proteins in the liver. Clin Pharmacol Ther  2012,92(5),599-612","journal-title":"Clin Pharmacol Ther"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S0016-5085(97)70239-7","volume":"112","author":"Setchell K.D.","year":"1997","unstructured":"Setchell K.D.; Rodrigues C.M.; Clerici C.; Solinas A.; Morelli A.; Gartung C.; Boyer J.; Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology  1997,112(1),226-235","journal-title":"Gastroenterology"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.gastro.2005.05.009","volume":"129","author":"Marschall H.","year":"2005","unstructured":"Marschall H.; Wagner M.; Zollner G.; Fickert P.; Diczfalusy U.; Gumhold J.; Silbert D.; Fuchsbichler A.; Benthin L.; Grundstr\u00f6m R.; Gustafsson U.; Sahlin S.; Einarsson C.; Trauner M.; Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology  2005,129(2),476-485","journal-title":"Gastroenterology"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/gut.51.1.113","volume":"51","author":"Milkiewicz P.","year":"2002","unstructured":"Milkiewicz P.; Roma M.G.; Elias E.; Coleman R.; Hepatoprotection with tauroursodeoxycholate and muricholate against taurolithocholate induced cholestasis: involvement of signal transduction pathways. Gut  2002,51(1),113-119","journal-title":"Gut"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1053\/jhep.2002.36088","volume":"36","author":"Paumgartner G.","year":"2002","unstructured":"Paumgartner G.; Beuers U.; Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited. Hepatology  2002,36(3),525-531","journal-title":"Hepatology"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1002\/hep.20246","volume":"39","author":"Schoemaker M.H.","year":"2004","unstructured":"Schoemaker M.H.; Conde de la Rosa L.; Buist-Homan M.; Vrenken T.E.; Havinga R.; Poelstra K.; Haisma H.J.; Jansen P.L.M.; Moshage H.; Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology  2004,39(6),1563-1573","journal-title":"Hepatology"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1194\/jlr.R900011-JLR200","volume":"50","author":"Amaral J.D.","year":"2009","unstructured":"Amaral J.D.; Viana R.J.S.; Ramalho R.M.; Steer C.J.; Rodrigues C.M.P.; Bile acids: Regulation of apoptosis by ursodeoxycholic acid. J Lipid Res  2009,50(9),1721-1734","journal-title":"J Lipid Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","volume":"32","author":"Par\u00e9s A.","year":"2000","unstructured":"Par\u00e9s A.; Caballer\u00eda L.; Rod\u00e9s J.; Bruguera M.; Rodrigo L.; Garc\u00eda-Plaza A.; Berenguer J.; Rodr\u00edguez-Mart\u00ednez D.; Mercader J.; Velicia R.; Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: Results of a double-blind controlled multicentric trial. J Hepatol  2000,32(4),561-566","journal-title":"J Hepatol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/gast.1996.v111.pm8698195","volume":"111","author":"Van Nieuwkerk C.M.","year":"1996","unstructured":"Van Nieuwkerk C.M.; Elferink R.P.; Groen A.K.; Ottenhoff R.; Tytgat G.N.; Dingemans K.P.; Van Den Bergh Weerman M.A.; Offerhaus G.J.; Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Gastroenterology  1996,111(1),165-171","journal-title":"Gastroenterology"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/MOG.0000000000000708","volume":"37","author":"Cazzagon N.","year":"2021","unstructured":"Cazzagon N.; Floreani A.; Primary biliary cholangitis: Treatment. Curr Opin Gastroenterol  2021,37(2),99-104","journal-title":"Curr Opin Gastroenterol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1053\/jhep.2002.32712","volume":"35","author":"Alpini G.","year":"2002","unstructured":"Alpini G.; Baiocchi L.; Glaser S.; Ueno Y.; Marzioni M.; Francis H.; Phinizy J.L.; Angelico M.; LeSage G.; Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha. Hepatology  2002,35(5),1041-1052","journal-title":"Hepatology"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","volume":"62","author":"Beuers U.","year":"2015","unstructured":"Beuers U.; Trauner M.; Jansen P.; Poupon R.; New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond. J Hepatol  2015,62(1)(Suppl.),S25-S37","journal-title":"J Hepatol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1172\/JCI1325","volume":"101","author":"Rodrigues C.M.","year":"1998","unstructured":"Rodrigues C.M.; Fan G.; Ma X.; Kren B.T.; Steer C.J.; A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest  1998,101(12),2790-2799","journal-title":"J Clin Invest"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jhep.2012.08.002","volume":"58","author":"Halilbasic E.","year":"2013","unstructured":"Halilbasic E.; Claudel T.; Trauner M.; Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol  2013,58(1),155-168","journal-title":"J Hepatol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s12177-009-9030-x","volume":"2","author":"Boatright J.H.","year":"2009","unstructured":"Boatright J.H.; Nickerson J.M.; Moring A.G.; Pardue M.T.; Bile acids in treatment of ocular disease. J Ocul Biol Dis Infor  2009,2(3),149-159","journal-title":"J Ocul Biol Dis Infor"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fnins.2015.00080","volume":"9","author":"Palmela I.","year":"2015","unstructured":"Palmela I.; Correia L.; Silva R.F.M.; Sasaki H.; Kim K.S.; Brites D.; Brito M.A.; Hydrophilic bile acids protect human blood-brain barrier endothelial cells from disruption by unconjugated bilirubin: An in vitro study. Front Neurosci  2015,9,80","journal-title":"Front Neurosci"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40659-023-00431-8","volume":"56","author":"Orozco-Aguilar J.","year":"2023","unstructured":"Orozco-Aguilar J.; Tacchi F.; Aguirre F.; Valero-Breton M.; Castro-Sepulveda M.; Simon F.; Cabello-Verrugio C.; Ursodeoxycholic acid induces sarcopenia associated with decreased protein synthesis and autophagic flux. Biol Res  2023,56(1),28","journal-title":"Biol Res"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s10044-017-0666-z","volume":"21","author":"Dura E.","year":"2018","unstructured":"Dura E.; Domingo J.; G\u00f6\u00e7eri E.; Mart\u00ed-Bonmat\u00ed L.; A method for liver segmentation in perfusion MR images using probabilistic atlases and viscous reconstruction. Pattern Anal Appl  2018,21(4),1083-1095","journal-title":"Pattern Anal Appl"},{"key":"ref=73","first-page":"1","author":"Goceri E.","year":"2013","unstructured":"Goceri E.;  A comparative evaluation for liver segmentation from spir images and a novel level set method using signed pressure force function  2013,1-136","journal-title":"A comparative evaluation for liver segmentation from spir images and a novel level set method using signed pressure force function"},{"key":"ref=74","first-page":"741","volume":"23","author":"G\u00f6\u00e7eri E.","year":"2015","unstructured":"G\u00f6\u00e7eri E.; \u00dcnl\u00fc M. Z.; Dicle O. J. T. J. o. E. E.; Sciences C.;  A comparative performance evaluation of various approaches for liver segmentation from SPIR images  2015,23(3),741-768","journal-title":"A comparative performance evaluation of various approaches for liver segmentation from SPIR images"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1109\/IPTA.2012.6469551","author":"Goceri E.","year":"2012","unstructured":"Goceri E.; Unlu M.Z.; Guzelis C.; Dicle O.; In an automatic level set based liver segmentation from MRI data sets. 2012 3rd International Conference on Image Processing Theory, Tools and Applications (IPTA)  2012,192-197","journal-title":"2012 3rd International Conference on Image Processing Theory, Tools and Applications (IPTA)"}],"container-title":["Current Protein &amp; Peptide Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389203724666230818092800","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/219967\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389203724666230818092800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T01:41:10Z","timestamp":1711330870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/219967\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389203724666230818092800","relation":{},"ISSN":["1389-2037"],"issn-type":[{"value":"1389-2037","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-03-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}